

Functional gastrointestinal disorders: Insights into diagnosis and treatment strategies.

Leonid Kesh*

Department of Physical Therapy, Ben Gurion University of the Negev, Israel

Introduction

Functional Gastrointestinal Disorders (FGIDs) are a group of disorders characterized by chronic or recurrent gastrointestinal symptoms without evidence of structural or biochemical abnormalities. These conditions are highly prevalent, affecting individuals of all ages and significantly impacting their quality of life. Diagnosing and managing FGIDs pose challenges to healthcare providers due to the complexity of symptoms and the absence of clear biomarkers. However, advancements in understanding the pathophysiology of FGIDs have led to improved diagnostic criteria and treatment strategies [1].

The diagnosis of FGIDs relies primarily on clinical evaluation and symptom-based criteria. Healthcare providers use established guidelines, such as the Rome criteria, to classify FGIDs based on symptom patterns and duration. Common FGIDs include Irritable Bowel Syndrome (IBS), functional dyspepsia, functional bloating, and functional constipation. Healthcare providers conduct a thorough history and physical examination to assess symptoms, identify potential triggers or exacerbating factors, and rule out alarm features that may suggest organic disease [2,3].

FGIDs are diagnosed based on specific symptom criteria outlined in the Rome criteria, which are periodically updated to reflect advances in the understanding of gastrointestinal disorders. In selected cases, additional testing may be performed to exclude organic diseases or identify specific physiological abnormalities. This may include blood tests, stool studies, imaging studies (e.g., abdominal ultrasound, MRI), and endoscopic procedures (e.g., colonoscopy, upper endoscopy). The pathophysiology of FGIDs is multifactorial and involves complex interactions between biological, psychological, and social factors. Key mechanisms implicated in FGIDs include altered gut motility, visceral hypersensitivity, gut-brain axis dysfunction, immune dysregulation, and altered gut microbiota composition [4].

Dysregulated motor function of the gastrointestinal tract, characterized by abnormalities in peristalsis and transit, contributes to symptoms such as abdominal pain, bloating, and altered bowel habits. Heightened sensitivity to visceral stimuli, including distension and contraction of the gut, leads to exaggerated perception of pain and discomfort in response to normal physiological processes [5,6].

Bidirectional communication between the gut and the central nervous system is disrupted in FGIDs, resulting in aberrant processing of sensory signals and alterations in emotional and cognitive responses to gastrointestinal symptoms. Low-grade inflammation and immune activation have been observed in some patients with FGIDs, suggesting a potential role of immune dysregulation in symptom generation and exacerbation [7].

Disturbances in the composition and function of the gut microbiota, known as dysbiosis, have been implicated in FGIDs. Changes in microbial diversity, abundance of specific bacterial species, and metabolite production may influence gut function and symptom expression. The management of FGIDs is aimed at alleviating symptoms, improving quality of life, and addressing comorbidities. Treatment strategies encompass a multidisciplinary approach, including lifestyle modifications, dietary interventions, pharmacotherapy, psychological therapies, and complementary and alternative medicine [8].

Patients are advised to adopt healthy lifestyle habits, such as regular physical activity, stress management techniques, and adequate sleep hygiene, to promote gastrointestinal health and symptom relief. Dietary modifications, such as the low FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols) diet, may be beneficial for reducing symptoms of bloating, abdominal pain, and altered bowel habits in select patients [9].

Various medications are available for managing specific symptoms of FGIDs, including antispasmodics, laxatives, prokinetics, antidepressants, and anti-anxiety agents. Treatment decisions are tailored to individual patient needs and symptom profiles. Cognitive-Behavioral Therapy (CBT), gut-directed hypnotherapy and relaxation techniques can help modulate the brain-gut axis, reduce symptom severity, and improve coping skills in patients with FGIDs. Some patients may benefit from complementary approaches, such as acupuncture, probiotics, herbal supplements, and mind-body practices, as adjunctive therapies for symptom management [10].

Conclusion

Functional gastrointestinal disorders pose significant diagnostic and therapeutic challenges due to the heterogeneous nature of symptoms and the absence of specific biomarkers.

*Correspondence to: Leonid Kesh, Department of Physical Therapy, Ben Gurion University of the Negev, Israel. E-mail: kleo1234@bgu.ac.il

Received: 09-Feb-2024, Manuscript No. AAAGIM-24-136848; Editor assigned: 13-Feb-2024, PreQC No. AAAGIM-24-136848(PQ); Reviewed: 22-Feb-2024, QC No. AAAGIM-24-136848; Revised: 26-Feb-2024, Manuscript No. AAAGIM-24-136848(R); Published: 29-Feb-2024, DOI: 10.35841/aaagim-8.1.219

However, advances in understanding the pathophysiology of FGIDs have paved the way for more targeted approaches to diagnosis and treatment. By adopting a comprehensive and multidisciplinary approach, healthcare providers can effectively manage FGIDs, alleviate symptoms, and improve the quality of life for affected individuals.

References

1. Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. *Curr Opin Rheumatol.* 2022;34(6):328-36.
2. Ge L, Liu S, Li S, et al. Psychological stress in inflammatory bowel disease: Psychoneuroimmunological insights into bidirectional gut–brain communications. *Front Immunol.* 2022;13:1016578.
3. Hemming ML, Heinrich MC, Bauer S, et al. Translational insights into gastrointestinal stromal tumor and current clinical advances. *Ann Oncol.* 2018;29(10):2037-45.
4. Li K, Ruan G, Liu S, et al. Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment. *Chin Med J (Engl).* 2023;136(8):899-909.
5. Hackam DJ, Sodhi CP, Good M. New insights into necrotizing enterocolitis: from laboratory observation to personalized prevention and treatment. *J Pediatr Surg.* 2019;54(3):398-404.
6. Li C, Wang Q, Jiang KW, et al. Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis. *Eur J Surg Oncol.* 2023;49(12):107079.
7. Cao H, Zhu Y, Hu G, et al. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?. *Pharmacol Res.* 2023;187:106586.
8. Lin H, Yu Y, Zhu L, et al. Implications of hydrogen sulfide in colorectal cancer: Mechanistic insights and diagnostic and therapeutic strategies. *Redox Biol.* 2023;59:102601.
9. Baharudin R, Rus Bakaruraini NQ, Ismail I, et al. MicroRNA methylome signature and their functional roles in colorectal cancer diagnosis, prognosis, and chemoresistance. *Int J Mol Sci.* 2022;23(13):7281.
10. Liu L, Wang H, Chen X, et al. Gut microbiota: A new insight into neurological diseases. *Chin Med J (Engl).* 2023;136(11):1261-77.